Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:14:43 EDT Fri 11 Jul 2025
Enter Symbol
or Name
USA
CA



Z:LLY - ELI LILLY AND COMPANY - https://www.lilly.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LLY - Z0.2788.14·792.980.2792.89+2.240.32,852.52,235,04657,366786.22  795.61  777.20972.53  677.091219:57:58Jul 0915 min RT 2¢

Recent Trades - Last 10 of 57366
Time ETExPriceChangeVolume
19:57:58Z791.99131.341315
19:57:13Z792.011.361
19:56:48Z792.011.362
19:55:58Z792.011.362
19:55:39Z792.952.301
19:54:16Z792.992.342
19:53:39Z792.4551.8051
19:50:46Z792.882.2340
19:47:20Z792.011.361
19:43:18Z791.94671.29671

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-09 06:45U:LLYNews ReleaseFDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
2025-06-23 11:37U:LLYNews ReleaseLilly declares third-quarter 2025 dividend
2025-06-22 14:31U:LLYNews ReleaseLilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
2025-06-21 09:01U:LLYNews ReleaseLilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
2025-06-17 06:45U:LLYNews ReleaseLilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
2025-06-16 06:45U:LLYNews ReleaseLilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
2025-06-02 10:00U:LLYNews ReleaseLilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
2025-06-02 08:00U:LLYNews ReleaseLilly presents first clinical data for its investigational, next-generation FRalpha targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
2025-05-29 17:00U:LLYNews ReleaseLilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
2025-05-27 10:00U:LLYNews ReleaseLilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
2025-05-22 17:05U:LLYNews ReleaseLilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-05-21 16:21U:LLYNews ReleaseLilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
2025-05-11 18:01U:LLYNews ReleaseZepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
2025-05-09 08:00U:LLYNews ReleaseLilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
2025-05-08 06:45U:LLYNews ReleaseLilly announces transitions in executive leadership
2025-05-05 12:47U:LLYNews ReleaseLilly declares second-quarter 2025 dividend
2025-05-02 10:00U:LLYNews ReleaseLilly to participate in Bank of America Securities 2025 Healthcare Conference
2025-05-01 06:45U:LLYNews ReleaseLilly reports first-quarter 2025 financial results and highlights pipeline momentum
2025-04-17 10:00U:LLYNews ReleaseLilly confirms date and conference call for first-quarter 2025 financial results announcement
2025-04-17 06:45U:LLYNews ReleaseLilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial